CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells. CODA’s engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.